Medacta Beats H2 Estimates, Maintains 2026 Guidance

Key Financial Highlights

Swiss medical device maker Medacta Group SA reported second-half adjusted EBIT of €52 million and adjusted EBITDA of €92 million, exceeding consensus expectations by 1% and 3% respectively. The positive results were primarily driven by effective management of operating expenses.

Performance Overview

The company's previously disclosed group sales demonstrated strong performance, growing 17% in constant currency during the second half. Additionally, free cash flow to equity showed a significant improvement, registering a negative €3 million for the period compared to a negative €8 million previously.

Future Outlook and Guidance

Looking ahead, Medacta's management maintained its 2026 guidance, projecting revenue growth of 10-14% in constant currency and an EBITDA margin expansion of 50 basis points. The company also updated its mid-term guidance for 2024-27, raising its constant currency revenue growth forecast to a range of 12-15%.

Summary

Medacta's solid second-half performance and confident forward guidance signal strong operational control and a positive outlook. The company's updated targets align with market expectations and suggest a trajectory of sustained growth in the coming years.

FAQ

Q: What were Medacta's key financial results for the second half?
A: The company reported a second-half adjusted EBIT of €52 million and adjusted EBITDA of €92 million, with sales growing 17% in constant currency.

Q: What is Medacta's financial guidance for 2026?
A: Medacta projects revenue growth between 10-14% in constant currency, along with a 50 basis point expansion in its constant currency EBITDA margin.

Source: Investing.com